Journal of cardiology最新文献

Background: Hypertrophic cardiomyopathy (HCM) is a common genetic disease with estimated prevalence of 0.2-0.5 %. Contemporary management has substantially improved HCM outcomes. However, the impact of HCM on critically ill patients admitted to intensive care units (ICU) has not been well studied.

Methods: Unmatched and propensity score matched patients with or without HCM were examined in the MIMIC-IV database and compared for mortality, morbidity, and length of stay. Multivariable logistic regression was used to identify risk factors associated with in-hospital mortality in patients with HCM.

Results: Of 51,926 critically ill patients, 165 (0.32 %) were also diagnosed with HCM. Compared with those without HCM, patients with HCM had higher body mass index, higher rates of heart failure, atrial fibrillation, and chronic renal disease, and more often had implantable cardioverter defibrillators. There were no significant differences in in-hospital mortality (10.3 % vs 10.2 %) or length of stay (9.3 ± 9.6 vs 9.3 ± 1 0.6 days) between the two groups. Similar results were obtained in propensity score matched patients with or without HCM. Univariable analyses identified respiratory failure, sepsis, use of vasopressors, and circulatory support devices as predictors of in-hospital mortality in adults with HCM. In multivariable logistic regression analysis, respiratory failure and use of vasopressors and circulatory support devices were the predictors of in-hospital mortality in HCM patients.

Conclusions: Presence of HCM did not affect in-hospital mortality in critically ill patients, but the need for vasopressors and circulatory support devices predicted worse in-hospital mortality among critically ill patients with HCM.

Approximately 10 % of patients who have suffered from myocardial infarction develop new-onset atrial fibrillation (AF). Coronary artery disease implicating atrial branches has been associated with AF. The following variables have been associated with new-onset AF in the setting of acute coronary syndrome: older age, history of hypertension, history of angina, history of stroke, chronic renal failure, body mass index, no statin use, worse nutritional status, worse Killip class, admission heart rate ≥ 85 bpm, complete atrioventricular block, Glasgow prognostic score, Syntax score, C₂HEST score > 3, PRECISE-DAPT score ≥ 25, left ventricular ejection fraction ≤40 %, increased left atrial diameter, E/E' ratio > 12, epicardial fat tissue thickness, and thrombolysis in myocardial infarction flow < 3. Regarding laboratory variables, elevated D-dimer levels, C-reactive protein levels, N-terminal pro-B-type natriuretic peptide, creatine kinase-MB, high-sensitivity troponin T at baseline, midregional pro-atrial natriuretic peptide, and cholesterol levels have been proposed as potential predictors of AF in this setting. Regarding the impact of new-onset AF on clinical outcomes, it has been associated with an increased risk of stroke, higher mortality rates, heart failure, cardiogenic shock, higher odds of ventricular arrhythmias and major adverse cardiac events. New-onset AF is an indicator of worse in-hospital prognosis compared to patients with a previous history of AF. New-onset AF, as well as previous AF, were strong predictors of ischemic stroke, and therefore, patients with new-onset AF should be anticoagulated according to the CHA₂DS₂-VASc score. Cardioversion to sinus rhythm, if possible, is advised before the discharge as it may be related to better outcomes.

Coronary artery calcium (CAC) score is a neglected biomarker that can be derived from non-cardiac chest computed tomography scan and represents a surrogate for atherosclerosis. We created a simulation model using different CAC score values in the MESA coronary artery risk score in a population derived from the Fourier Trial. CAC score could modulate the sample sizes of cardiovascular trials in primary and secondary prevention and offer new primary prevention treatments to high-risk subjects with reasonable numbers needed to treat comparable to secondary prevention trials.

Background: Patients with diabetes mellitus (DM) are particularly susceptible to contrast-associated acute kidney injury (CA-AKI). However, few studies have evaluated CA-AKI stages in patients with DM following elective percutaneous coronary intervention (PCI) with iodixanol.

Methods: Patients with DM who underwent elective PCI in 8 Chinese hospitals from May 2020 to November 2021 were prospectively enrolled in the Iodixanol-Acute Kidney Injury Registry (No. ChiCTR1800016719). According to the European Society of Urogenital Radiation on their CA-AKI diagnosis, and follow-up of major adverse renal and cardiovascular events (MARCE), CA-AKI and prognosis predictors were identified using logistic and Cox multivariable regression, respectively.

Results: There were 1120 patients with DM included and the incidence of CA-AKI was 5.8 % (65/1120). However, most CA-AKI patients were at acute kidney injury stage 1 (96.9 %, 63/65). The dose of iodixanol was not an independent risk factor for CA-AKI, however, a hemoglobin level <110 g/L, a left ventricular ejection fraction (LVEF) <40 %, an estimated glomerular filtration rate <60 mL/min/1.73m², an N-terminal pro-B-type natriuretic peptide level ≥300 pg/mL, and the use of loop diuretics were independent risk factors. Only 3.5 % (39/1120) of patients experienced MARCE. Hypertension, LVEF <40 %, hemoglobin level <110 g/L, and age >75 years old were independent risk factors for MARCE, while in comparison to indobufen, aspirin is an independent protective factor against MARCE in diabetic patients.

Conclusions: The incidence of CA-AKI in patients with DM who underwent PCI was low, mostly associated with mild renal impairment, and therefore did not increase the risk of MARCE.

Right ventricular (RV) longitudinal strain has emerged as a crucial tool for evaluating RV systolic function in patients with heart disease. The complex anatomy of the RV presents challenges for functional assessment, traditionally conducted using conventional parameters, such as tricuspid annular plane systolic excursion and RV fractional area change. While these conventional methods are simple and practical, they have limitations in reflecting the majority of global RV systolic function. In contrast, RV longitudinal strain, measured using speckle tracking echocardiography, offers a more accurate evaluation of RV systolic function with high reproducibility. It is less dependent on angle and load and utilizes automated techniques. The utility of RV longitudinal strain in patients with valvular heart disease has been reported, showing its effectiveness in detecting early RV systolic dysfunction and providing valuable prognostic information compared to conventional methods. Treatment options for valvular heart disease include not only traditional open-heart surgery but also catheter-based interventions, which have become increasingly available in recent years. In addition to conventional risk assessment, considering treatment choices based on RV systolic function may be beneficial. This approach could provide a new method for determining the optimal treatment plan for individual patients. Despite challenges such as imaging quality and vendor-specific variability, RV longitudinal strain remains a valuable tool for early detection of RV systolic dysfunction, optimizing patient management, and improving outcomes. This review examines the clinical utility of RV longitudinal strain in patients with valvular heart disease, focusing on its prognostic value and role in patient management.